Skip to main content
Erschienen in: Investigational New Drugs 4/2013

01.08.2013 | PHASE II STUDIES

A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors

verfasst von: Darren R. Feldman, Lawrence H. Einhorn, David I. Quinn, Yohann Loriot, Johnathan K. Joffe, David J. Vaughn, Aude Fléchon, Julio Hajdenberg, Abdel-Baset Halim, Hamim Zahir, Robert J. Motzer

Erschienen in: Investigational New Drugs | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Summary

Background Tivantinib is a selective, small-molecule inhibitor of the MET receptor tyrosine kinase. Preclinical and phase 1 data suggested a possible role for MET in the pathophysiology of germ cell tumors (GCTs) and a potential clinical benefit from tivantinib in patients with these tumors. Methods Men (≥16 years) with relapsed or refractory, histologically confirmed, non-central nervous system GCTs received oral tivantinib 360 mg twice daily in 28-day cycles until progressive disease or unacceptable toxicity. The primary endpoint was objective response rate in the first 4 cycles, with study termination for <2 responses among the first 21 patients. Secondary endpoints included 12-week progression-free survival (PFS), overall survival (OS), and safety. Results Twenty-seven patients were enrolled in 9 months (median age, 32 years). Most patients had tumors with nonseminoma histology (n = 25), and primary tumor sites were testis (n = 24) and mediastinum (n = 3). Among 25 evaluable patients, no objective responses were observed; accrual was halted when the 21st patient became evaluable. Best response was stable disease (n = 5). Median PFS was 1 month, the 12-week PFS rate was 21 %, and median OS was 6 months. Grade 3 or 4 adverse events considered related to study drug included grade 3 pneumonia and grade 3 syncope (n = 1, each). Conclusions Tivantinib was well tolerated but did not demonstrate single-agent activity in patients with relapsed/refractory GCTs. Rapid accrual to this phase 2 trial was achieved in this rare patient population through multicenter collaboration.
Literatur
4.
Zurück zum Zitat Qiao H, Hung W, Tremblay E et al (2002) Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem 86:665–677. doi:10.1002/jcb.10239 PubMedCrossRef Qiao H, Hung W, Tremblay E et al (2002) Constitutive activation of met kinase in non-small-cell lung carcinomas correlates with anchorage-independent cell survival. J Cell Biochem 86:665–677. doi:10.​1002/​jcb.​10239 PubMedCrossRef
5.
Zurück zum Zitat Takayama H, LaRochelle WJ, Sharp R et al (1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 94:701–706PubMedCrossRef Takayama H, LaRochelle WJ, Sharp R et al (1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A 94:701–706PubMedCrossRef
6.
Zurück zum Zitat Takeuchi H, Bilchik A, Saha S et al (2003) c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9:1480–1488PubMed Takeuchi H, Bilchik A, Saha S et al (2003) c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 9:1480–1488PubMed
9.
Zurück zum Zitat Daiichi Sankyo Inc (2009) Data on file Daiichi Sankyo Inc (2009) Data on file
10.
Zurück zum Zitat Munshi N, Jeay S, Li Y et al (2010) ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9:1544–1553PubMedCrossRef Munshi N, Jeay S, Li Y et al (2010) ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 9:1544–1553PubMedCrossRef
12.
Zurück zum Zitat Rosen LS, Senzer N, Mekhail T et al (2011) A phase I dose-escalation study of tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 17:7754–7764PubMedCrossRef Rosen LS, Senzer N, Mekhail T et al (2011) A phase I dose-escalation study of tivantinib (ARQ 197) in adult patients with metastatic solid tumors. Clin Cancer Res 17:7754–7764PubMedCrossRef
13.
Zurück zum Zitat Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedCrossRef
14.
Zurück zum Zitat Mekhail T, Rich T, Rosen L et al. (2009) Final results: a dose escalation phase I study of ARQ 197, a selective c-MET inhibitor, in patients with metastatic solid tumors. J Clin Oncol 27:Abstract 3548 Mekhail T, Rich T, Rosen L et al. (2009) Final results: a dose escalation phase I study of ARQ 197, a selective c-MET inhibitor, in patients with metastatic solid tumors. J Clin Oncol 27:Abstract 3548
17.
Zurück zum Zitat Feldman DR, Patil S, Trinos MJ et al (2012) Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer 118:981–986. doi:10.1002/cncr.26375 PubMedCrossRef Feldman DR, Patil S, Trinos MJ et al (2012) Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design. Cancer 118:981–986. doi:10.​1002/​cncr.​26375 PubMedCrossRef
18.
Zurück zum Zitat Detre S, Saclani Jotti G, Dowsett M (1995) A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48:876–878PubMedCrossRef Detre S, Saclani Jotti G, Dowsett M (1995) A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48:876–878PubMedCrossRef
19.
Zurück zum Zitat Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R (2007) High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357:340–348. doi:10.1056/NEJMoa067749 PubMedCrossRef Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R (2007) High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med 357:340–348. doi:10.​1056/​NEJMoa067749 PubMedCrossRef
21.
22.
Zurück zum Zitat Kollmannsberger C, Beyer J, Liersch R et al (2004) Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 22:108–114. doi:10.1200/JCO.2004.06.068 PubMedCrossRef Kollmannsberger C, Beyer J, Liersch R et al (2004) Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 22:108–114. doi:10.​1200/​JCO.​2004.​06.​068 PubMedCrossRef
23.
Zurück zum Zitat Pectasides D, Pectasides M, Farmakis D et al (2004) Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 15:493–497PubMedCrossRef Pectasides D, Pectasides M, Farmakis D et al (2004) Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 15:493–497PubMedCrossRef
Metadaten
Titel
A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors
verfasst von
Darren R. Feldman
Lawrence H. Einhorn
David I. Quinn
Yohann Loriot
Johnathan K. Joffe
David J. Vaughn
Aude Fléchon
Julio Hajdenberg
Abdel-Baset Halim
Hamim Zahir
Robert J. Motzer
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Investigational New Drugs / Ausgabe 4/2013
Print ISSN: 0167-6997
Elektronische ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-013-9934-y

Weitere Artikel der Ausgabe 4/2013

Investigational New Drugs 4/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.